Roche Diagnostics supports Insulin Safety Week 2026 as part of commitment to diabetes care
A message from the organisers:
We have received funding by means of sponsorship, including from pharmaceutical and medical technology companies, to support the delivery of our campaign. Insulin Safety Week 2026 has been funded by Roche Diagnostics, MiniMed, Sanofi and Ascensia which have had no input into the campaign's arrangements or content.
Roche Diagnostics has been announced as an official sponsor of Insulin Safety Week 2026, supporting the campaign’s ongoing mission to improve insulin safety across healthcare settings.
Taking place from May 11 to 17 Insulin Safety Week brings together healthcare professionals from the UK and Northern Ireland to raise awareness of best practice in insulin use and reduce the risk of insulin-related harm.
Following a record-breaking 2025 campaign, which saw more than 800 healthcare sites – including hospitals and GP practices – take part, the initiative continues to grow in impact.
This year’s campaign will focus on the increasing role of technology in diabetes care. Advances such as smart insulin pens, insulin pumps integrated with monitoring apps, continuous glucose monitoring systems and hybrid closed-loop technologies are transforming how insulin is prescribed, delivered and managed.
Alongside these innovations, improved digital education tools, clinical decision-support systems and better data sharing are helping to support safer, more informed care.
Claire Marriott, Medical Affairs Lead at Roche Diagnostics, said: “Safe insulin use is fundamental to effective diabetes management, so we’re really proud to support Insulin Safety Week 2026 and the important work it does to keep safety front of mind across healthcare settings.
“As new technologies and tools for people living with diabetes become more advanced, it's so important that healthcare professionals have everything they need to be confident in using them safely and effectively.
“By supporting this campaign, we want to play our part in building that confidence and ultimately improve outcomes for people living with diabetes."
Roche Diagnostics has recently announced that its Accu-Chek® SmartGuide continuous glucose monitoring (CGM) system is now reimbursable on the NHS, giving adults living with diabetes easier access to the technology. This decision makes it the first artificial intelligence (AI)-driven CGM in the UK capable of predicting nighttime hypoglycaemia.
Using AI, the system analyses glucose patterns to forecast levels over the next 30 minutes, two hours and throughout the night, and prompts users to take action if their glucose is expected to drop below a safe range. A water-resistant sensor worn on the back of the upper arm sends readings to a smartphone app every five minutes, helping people stay informed and take action before low blood sugar becomes a problem.
There is still time for healthcare professionals to register to take part and access the Insulin Safety Week online resource pack, which includes practical materials to support awareness activities, team learning and conversations around best practice.
For more information and to register visit: www.insulinsafetyweek.com
We have received funding by means of sponsorship, including from pharmaceutical and medical technology companies, to support the delivery of our campaign. Insulin Safety Week 2026 has been funded by Roche Diagnostics, MiniMed, Sanofi and Ascensia which have had no input into the campaign's arrangements or content.